| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
J147 does not have a single defined target but is broadly neuroprotective. It protects against neurotoxicity in cortical neurons. It reduces soluble Aβ40 and Aβ42 levels and increases BDNF levels in the hippocampus in vivo. It is active in six different neurotoxicity assays.
|
|---|---|
| ln Vitro |
J-147 exhibits a dose-dependent effect on HT22 and primary cell mortality, with EC50 values spanning from 0.06-0.115 μM [2].
J147 protects against neurotoxicity in cortical neurons in vitro with an EC50 of 25-200 nM. It is a potent neurotrophic compound. Its activity is based on efficacy in multiple cellular models of age-associated pathologies, rather than a single enzymatic target. |
| ln Vivo |
J-147 (diet prepared with 200 ppm J-147; 6 months) increases memory and dendritic spine number in old mice [4]. The half-life (t1/2) of J-147 was determined at 1.5 hours in the braid
J147 enhances memory in wild-type rats. It prevents memory deficits and rescues cognitive deficits in young and aged transgenic Alzheimer's disease mouse models. It is an orally active and broadly neuroprotective compound. |
| Enzyme Assay |
J147's mechanism is not based on a single enzyme/receptor, so there is no standard binding assay. Its activity is assessed in cell-based neuroprotection assays. It is a phenotypic drug that was discovered based on its efficacy in cellular models.
|
| Cell Assay |
In vitro cellular assays for J147 involve treating primary cortical neurons with neurotoxic agents in the presence of the compound. Its ability to protect against neurotoxicity is measured by assessing cell viability. Its neurotrophic activity is assessed by measuring neurite outgrowth or the induction of BDNF.
|
| Animal Protocol |
Animal/Disease Models: 24 24-month-old male C57Bl/6 mice; and 2.5 hrs (hrs (hours)) in the brain (per oral formulation, single dose, 20 mg/kg)[2]. Used 8-month-old mice as control [4]
Doses: 200 ppm Route of Administration: Added 200 ppm to the diet; 6-month Experimental Results: When objects moved a large distance (135 degrees), both young and old All animals can recognize it, but when the object moves a smaller distance of 45 degrees, the recognition index (RI) of the aged mice decreases. The decrease in RI was reversed after J147 treatment. In vivo efficacy is evaluated in transgenic mouse models of Alzheimer's disease, where J147 is administered orally. Its effects on cognitive function, amyloid pathology, and neuroinflammation are assessed. It is also studied in models of accelerated aging. |
| ADME/Pharmacokinetics |
J147 is an orally active compound. Its pharmacokinetic properties support oral administration. It can cross the blood-brain barrier to reach its targets in the brain. Its molecular weight is 350.33 g/mol.
|
| Toxicity/Toxicokinetics |
Toxicological data for J147 is not detailed in the provided sources. It has been studied in animal models and is considered a research compound. Its safety profile would be established for therapeutic development. It is not an approved drug.
|
| References |
|
| Additional Infomation |
J147 is an aniline compound. J147 is an experimental drug that has been reported to be effective in mouse models of Alzheimer's disease and accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective candidate drug, initially developed to treat age-related neurodegenerative diseases that affect many pathways involved in the pathogenesis of diabetic neuropathy.
J147 is a promising neuroprotective compound that was discovered through a phenotypic screening approach. It is a curcumin derivative with a unique mechanism of action that involves multiple pathways. Its efficacy in multiple models of neurodegeneration and aging makes it a valuable research tool. |
| Molecular Formula |
C18H17F3N2O2
|
|---|---|
| Molecular Weight |
350.34
|
| Exact Mass |
350.124
|
| CAS # |
1146963-51-0
|
| Related CAS # |
1417911-00-2 (C13-labeled);1146963-51-0 (E/Z isomers);1807913-16-1 (E-isomer);
|
| PubChem CID |
25229652
|
| Appearance |
Off-white to pink solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
412.8±55.0 °C at 760 mmHg
|
| Flash Point |
203.5±31.5 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.515
|
| LogP |
5.61
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
481
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=C(C=C1)N(C(=O)C(F)(F)F)/N=C/C2=CC(=CC=C2)OC)C
|
| InChi Key |
HYMZAYGFKNNHDN-SSDVNMTOSA-N
|
| InChi Code |
InChI=1S/C18H17F3N2O2/c1-12-7-8-16(13(2)9-12)23(17(24)18(19,20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H,1-3H3/b22-11+
|
| Chemical Name |
2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide
|
| Synonyms |
J147 J 147 J-147.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~285.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.88 mg/mL (5.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.8 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.88 mg/mL (5.37 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8544 mL | 14.2719 mL | 28.5437 mL | |
| 5 mM | 0.5709 mL | 2.8544 mL | 5.7087 mL | |
| 10 mM | 0.2854 mL | 1.4272 mL | 2.8544 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03838185
Conditions:Alzheimer's DiseaseProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
